APLM
$19.50-0.01 (-0.05%)
Market OpenAs of Mar 17, 5:17 PM UTC
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$19.50
Potential Upside
5%
Whystock Fair Value$20.48
Price
UndervaluedFair ValueOvervalued
Fundamentals
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio inclu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$41.80M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.76
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-380.13%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.91
Recent News
No recent news found.